MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-101149-PIP01-23-M01

Scope of the Application

Active Substance(s)

elosulfase alfa (recombinant human N-acetylgalactosamine-6-sulfatase)

Condition(s)

Treatment of mucopolysaccharidosis, type IVA (Morquio-A syndrome)

Pharmaceutical Form(s)

Concentrate for solution for infusion (Sterile concentrate)

Route(s) of Administration

INTRAVENOUS USE

Name / Corporate name of the PIP applicant

BioMarin International Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, BioMarin International Limited submitted to the licensing authority on 21/08/2023 17:26 BST an application for a Modification

The procedure started on 01/09/2023 18:55 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101149-PIP01-23-M01

Of 12/09/2023 09:54 BST

On the adopted decision for elosulfase alfa (recombinant human N-acetylgalactosamine-6-sulfatase) (MHRA-101149-PIP01-23-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for elosulfase alfa (recombinant human N-acetylgalactosamine-6-sulfatase), Concentrate for solution for infusion , INTRAVENOUS USE .

This decision is addressed to BioMarin International Limited, Shanbally, Ringaskiddy, County Cork, IRELAND, P43 R298

ANNEX I

1. Waiver

1.1 Condition:

Not applicable.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of mucopolysaccharidosis, type IVA (Morquio-A syndrome).

2.2 Indication(s) targeted by the PIP:

Treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA).

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than18 years of age.

2.4 Pharmaceutical Form(s):

Concentrate for solution for infusion.

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	5	Study 1 (BMN110-10-008 (CRL No. NJD00033)) Embryo-foetal development in rabbits (dose range finding). Study 2 (BMN110-10-007 (CRL No. NJD00032)) Combined fertility and embryo-foetal developmental study in rats. Study 3 (BMN110-10-061 (CRL No. NJD00034)) Embryo-foetal development in rabbits. Study 4 (BMN110-12-013) Peri- and post-natal developmental study in rats. Study 5 (BMN110-10-110 (Covance Study No. 8237512)) Repeat dose toxicity and toxicokinetics study in monkey.
Clinical Studies	5	Study 6 (MOR-002) Open-label, multicentre, dose-escalation safety study in children from 5 to less than 18 years. Study 7 (MOR-100) Open-label, multicentre, extension study in adults and children from 5 years of age. Study 8 (MOR-004) Double-blind, randomised, multicentre, 3-arm, placebo-controlled, efficacy and safety study in adults and children from 5 years of age. Study 9 (MOR-007) Open-label, multicentre, safety and efficacy study in children under 5 years of age. Study 10 (MOR-005) Multicentre, extension study in children from 5 years to less than 18 years of age (and adults).

Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	30/04/2017
Deferral of one or more studies contained in the paediatric investigation plan:	Yes